Abstract HTML Views: 855 PDF Downloads: 144 Total Views/Downloads: 1304
Abstract HTML Views: 594 PDF Downloads: 119 Total Views/Downloads: 931
Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the inactivation of glucagon-like peptide-1 (GLP-1). This
protein, released from the gut following ingestion of a meal, stimulates insulin secretion and inhibits glucagon secretion.
Compared with other anti-diabetic drugs, the pharmacological characteristics of DDP-4 inhibitor include improvement in
postprandial hyperglycemia, low frequency of hypoglycemia, prevention of development of obesity, few adverse events.
Taking account of pharmacological characteristic and our therapeutic experiences with DPP-4 inhibitor, we believe that
DPP-4 inhibitor may be a useful and safe oral anti-diabetic drug for diabetes in the elderly people, diabetes complicated
with obesity, chronic hepatitis/liver cirrhosis, and steroid-induced diabetes.